Actively Recruiting
Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study
Led by Fudan University · Updated on 2025-11-19
80
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single-center real-world study aiming to explore predictive factors for the efficacy of CAR-T therapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).
CONDITIONS
Official Title
Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathological diagnosis confirmed as large B-cell lymphoma
- Patients with relapsed or refractory large B-cell lymphoma after second-line or higher systemic treatment
- Intend to receive CAR-T products approved by NMPA for R/R LBCL
- Understand and voluntarily sign informed consent; guardians sign if patient lacks full civil capacity
You will not qualify if you...
- Poor patient compliance
- Pregnant or breastfeeding
- Other conditions deemed unsuitable by the researcher for study inclusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200231
Actively Recruiting
Research Team
C
Chuanxu Liu, M.D
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here